Budget impact and cost-effectiveness: can we afford precision medicine in oncology?

References

• Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010;9:363–6.
   PubMed Web of Science ®Google Scholar
• Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol 2015;1:539–40.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119:1981–7.
   PubMed Web of Science ®Google Scholar
• Garau M, Towse A, Garrison L, Housman L, Ossa D. Can and should value-based pricing be applied to molecular diagnostics? Personal Med 2012;10:61–72.
   Web of Science ®Google Scholar
• Sanghera S, Orlando R, Roberts T. Economic evaluations and diagnostic testing: an illustrative case study approach. Int J Technol Assess Health Care 2013;29:53–60.
   PubMed Web of Science ®Google Scholar
• MacLeod TE, Harris AH, Mahal A. Stated and revealed preferences for funding new high-cost cancer drugs: a critical review of the evidence from patients, the public and payers. Patient 2015;9:201–22.
   Google Scholar
• Shah KK, Tsuchiya A, Wailoo AJ. Valuing health at the end of life: a stated preference discrete choice experiment. Soc Sci Med 2015;124:48–56.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York: Oxford University Press Inc.; 2005.
   Google Scholar
• Doble B, Tan M, Harris A, Lorgelly P. Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Rev Mol Diagnos 2015;15:235–54.
   PubMed Web of Science ®Google Scholar
• Doble B, Harris A, Thomas DM, Fox S, Lorgelly P. Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics 2013;14:1405–17.
   PubMed Web of Science ®Google Scholar
• Doble B, Lorgelly P. Clinical players and healthcare payers: aligning perspectives on the cost–effectiveness of next-generation sequencing in oncology. Personal Med 2015;12:9–12.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare (AIHW). Health system expenditure on cancer and other neoplasms in Australia: 2008-09. Canberra: AIHW; 2013.
   Google Scholar
• Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Economics 2015;19: 1–16.
   PubMed Web of Science ®Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72.
   PubMed Web of Science ®Google Scholar
• Grosse SD, McBride CM, Evans JP, Khoury MJ. Personal utility and genomic information: look before you leap. Genet Med 2009;11:575–6.
   PubMed Web of Science ®Google Scholar
• Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726–34.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015;373:2005–14.
   PubMed Web of Science ®Google Scholar
• Towse A, Garrison LP Jr, economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health 2013;16:S39–43.
   PubMed Web of Science ®Google Scholar
• Hay JW. Evaluation and review of pharmacoeconomic models. Expert Opin Pharmacother 2004;5:1867–80.
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Bilger M, Flynn TN, Malhotra C. Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: a discrete choice experiment. Health Policy 2015;119:1482–9.
   PubMed Web of Science ®Google Scholar
• Seabury SA, Goldman DP, Maclean JR, Penrod JR, Lakdawalla DN. Patients value metastatic cancer therapy more highly than is typically shown through traditional estimates. Health Aff (Millwood) 2012;31:691–9.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Romley JA, Sanchez Y, Maclean JR, Penrod JR, Philipson T. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood) 2012;31:676–82.
   PubMed Web of Science ®Google Scholar
• Collins M, Latimer N. NICE’s end of life decision making scheme: impact on population health. BMJ 2013;346:f1363.
   PubMed Web of Science ®Google Scholar
• Prasad V, Kim C, Burotto M, Vandross A. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 2015;175:1389–98.
   PubMed Web of Science ®Google Scholar
• Hansen AR, Siu LL. PD-L1 Testing in cancer: challenges in companion diagnostic development. JAMA Oncol 2015;2:15–2.
   Web of Science ®Google Scholar